Compare Eli Lilly And Co (LLY) vs Zillow Group Inc Class C (Z) Price & Performance

Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.

Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.

Zillow Group (Z) trades at $33.26, down 1.45% on the day, amid a bearish technical signal and mixed sentiment. The stock shows strong revenue growth, with Q2 2026 results beating expectations, but faces near-term pressure from a securities class action lawsuit. Valuation metrics like a P/E of 148.41 reflect high growth expectations, while profitability remains modest with a net income margin of 1.96%.

The outlook is cautious; analyst consensus targets $52.00, implying upside, but legal risks and a challenging real estate market pose headwinds. Investors should weigh the company's monetization progress against litigation overhangs and macroeconomic sensitivity for balanced risk-reward assessment.